Weizmann Australia is a non-profit organisation dedicated to promoting the work of the Weizmann Institute of Science in Israel and the development of Australian scientific research and education. In doing so, we enable mutually beneficial engagement between Australian scientists and the Weizmann Institute in research and education programs.

The Weizmann Institute is one of the highest-ranking multidisciplinary scientific research institutes in the world with dedicated scientists working on more than a thousand projects ranging from cancer to computer science, from nutrition to nanotechnology, from Alzheimer’s to astrophysics. Weizmann scientists follow their curiosity to make discoveries aiming to solve humanity’s greatest challenges.

The Weizmann Institute shares rewarding long-term relationships around the world through it’s global family of satellite offices in the US, Europe, UK, Canada, and Latin America. Australia joined this family when Weizmann Australia was established in 2009.

More specifically, Weizmann Australia focuses on:

  • Collaboration – building networks that lead to and support research collaboration between the Weizmann Institute and Australia
  • Philanthropy – facilitating philanthropic investment for the invaluable research of the Weizmann Institute and its Australian partnerships.
  • Communication – highlighting the Weizmann Institute’s scientific discoveries and breakthroughs to Australian supporters and the general public
  • Education – delivering public benefit through events and educational programs that provide unique access to inspirational scientists, cutting – edge research and science education programs.

In 2016 a partnership with the Garvan Institute of Medical Research was created.  The Garvan-Weizmann Partnership has harnessed the complementary expertise of these two world-class research institutes.  Through joint research projects, staff and student exchange and cutting edge technologies, Garvan and Weizmann scientists are uncovering new insights into autoimmune diseases, cancers, type 2 diabetes and genomics to bring the latest scientific discoveries for the improvement of human health.


  • Stephen Chipkin (Chair)
  • Rina Michael (Executive Director)
  • Dan Bennett
  • Professor David Celermajer AO
  • Jacqui Scheinberg